Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul 15;12(1):417.
doi: 10.1186/s13104-019-4460-4.

Evolutionary trends in the prevalence of anti-HDV antibodies among patients positive for HBsAg referred to a national laboratory in Cameroon from 2012 to 2017

Laurence Noubissi-Jouegouo  1   2 , Marie Amougou Atsama  1 , Paul Alain Tagnouokam-Ngoupo  1 , Chavely Gwladys Monamele  1 , Laure Ngono  1 , Richard Njouom  3
Affiliations

Evolutionary trends in the prevalence of anti-HDV antibodies among patients positive for HBsAg referred to a national laboratory in Cameroon from 2012 to 2017

Laurence Noubissi-Jouegouo et al. BMC Res Notes. .

Abstract

Objective: The aim of this study was to update the data on the prevalence of anti-HDV antibodies in Cameroon.

Results: Antibodies against hepatitis Delta virus (Anti-HDV) were found in 16.48% (95% CI 11.46-18.77%) of 426 hepatitis B virus surface antigen positive patients in Cameroon. Remarkably, they were significantly higher among people over 40 years and those living in the East and South regions of Cameroon at 66.7%, 50%, and 40%, respectively. These results suggest that older age and living in areas in the dense forest may be risk factors for Hepatitis D infection.

Keywords: Anti-HDV antibodies; Cameroon; HBsAg; Prevalence; Trends.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Temporal trend of HDV infection over time
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Botelho-Souza LF, Vasconcelos MPA, dos Santos ADO, Salcedo JMV, Vieira DS. Hepatitis delta: virological and clinical aspects. Virol J. 2017;14:177. doi: 10.1186/s12985-017-0845-y. - DOI - PMC - PubMed
    1. Andernach IE, Leiss LV, Tarnagda ZS, Tahita MC, Otegbayo JA, Forbi JC, et al. Characterization of hepatitis Delta virus in Sub-Saharan Africa. J Clin Microbiol. 2014;52:1629–1636. doi: 10.1128/JCM.02297-13. - DOI - PMC - PubMed
    1. OMS. Global hepatitis report, 2017. 2017. http://www.who.int/news-room/fact-sheets/detail/hepatitis-d.
    1. Lempp FA, Ni Y, Urban S. Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options. Nat Rev Gastroenterol Hepatol. 2016;13:580–589. doi: 10.1038/nrgastro.2016.126. - DOI - PubMed
    1. Gheorghe L, Csiki IE, Iacob S, Gheorghe C, Trifan A, Grigorescu M, et al. Hepatitis Delta virus infection in Romania: prevalence and risk factors. J Gastrointestin Liver Dis. 2015;24:413–421. - PubMed

MeSH terms

Substances